BPGbio Sponsors Mitochondrial Medicine 2024 Conference
June 20 2024 - 7:00AM
Business Wire
BPGbio Showcases Mitochondrial Medicine
Advancements Driven by its Pioneering Biology-First, AI-Powered
Approach to Drug Development
BPGbio, Inc., a leading biology-first, AI-powered, clinical
stage biopharma focused on mitochondrial biology and protein
homeostasis, today announced its sponsorship and participation in
the United Mitochondrial Disease Foundation’s Mitochondrial
Medicine Conference taking place June 26-29, 2024 in Cleveland,
Ohio.
In its presentation and booth at this year’s Mitochondrial
Medicine conference, BPGbio will showcase the success of its
proprietary Interrogative Biology Platform, NAi, in advancing its
mitochondrial-biology focused clinical compound BPM31510, currently
in two active phase 2 trials in aggressive cancers, and exploring
phase 3 trials for primary CoQ10 deficiency and primary
mitochondrial disease.
Derived by the NAi Interrogative Platform, BPM31510(IV) is a
novel, highly bioavailable, CoQ10 metabolic approach to therapy. In
clinical trials, BPM31510 has demonstrated the benefit of
increasing levels of CoQ10 in cancer cells, restoring the normal
process of energy generation in the mitochondria leading to tumor
cell death. This revolutionary lipid conjugate molecule addresses
CoQ10 bioavailability issues in many mitochondrial diseases by
restoring CoQ10 levels to overcome the effect of mutations in genes
that lead to mitochondrial dysfunction. This restoration of energy
generation can minimize tissue damage from toxic metabolites and
preserve function in organs, such as the brain and heart.
“As BPGbio explores late-stage trials for primary CoQ10
deficiency and primary mitochondrial disease with BPM31510, we look
forward to joining the conversation at this year’s conference which
brings together the foremost experts and advocates in the
scientific, industry, and patient communities, as we work together
towards better mitochondrial disease treatment options and improved
patient outcomes,” said Niven R. Narain, Ph.D., Chairman, CEO and
President of BPGbio.
Mitochondrial diseases are considered rare, but their exact
prevalence can be challenging to determine due to their wide range
of symptoms and varying severity. Estimates suggest that
mitochondrial diseases affect about 1 in 4,300 to 1 in 5,000
individuals worldwide.
About BPGbio Inc.
BPGbio is a leading biology-first AI-powered clinical stage
biopharma focused on mitochondrial biology and protein homeostasis.
The company has a deep pipeline of AI-developed therapeutics
spanning oncology, rare disease and neurology, including several in
late-stage clinical trials. BPGbio’s novel approach is underpinned
by NAi, its proprietary Interrogative Biology Platform, protected
by over 400 US and international patents; one of the world’s
largest clinically annotated non-governmental biobanks with
longitudinal samples; and exclusive access to the most powerful
supercomputer in the world. With these tools, BPGbio is redefining
how patient biology can be modeled using bespoke Bayesian AI
specifically designed for solving large-scale biology challenges.
Headquartered in greater Boston, the company is at the forefront of
a new era in medicine, combining biology, multi-modal data, and AI
to transform the way we understand, diagnose, and treat disease.
For more information, visit www.bpgbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620833506/en/
media@bpgbio.com